- Home
- ACAD vs POR Comparison
ACAD vs POR Comparison
Compare ACAD & POR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- POR
- Stock Information
- Founded
- ACAD 1993
- POR 1889
- Country
- ACAD United States
- POR United States
- Employees
- ACAD N/A
- POR N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- POR Electric Utilities: Central
- Sector
- ACAD Health Care
- POR Utilities
- Exchange
- ACAD Nasdaq
- POR Nasdaq
- Market Cap
- ACAD 3.8B
- POR 4.4B
- IPO Year
- ACAD 2004
- POR N/A
- Fundamental
- Price
- ACAD $20.98
- POR $41.12
- Analyst Decision
- ACAD Buy
- POR Hold
- Analyst Count
- ACAD 18
- POR 11
- Target Price
- ACAD $27.71
- POR $46.50
- AVG Volume (30 Days)
- ACAD 2.1M
- POR 1.3M
- Earning Date
- ACAD 08-05-2025
- POR 07-25-2025
- Dividend Yield
- ACAD N/A
- POR 5.06%
- EPS Growth
- ACAD N/A
- POR 8.87
- EPS
- ACAD 1.37
- POR 2.86
- Revenue
- ACAD $996,283,000.00
- POR $3,439,000,000.00
- Revenue This Year
- ACAD $13.39
- POR $5.23
- Revenue Next Year
- ACAD $10.59
- POR $4.25
- P/E Ratio
- ACAD $15.33
- POR $14.38
- Revenue Growth
- ACAD 22.42
- POR 10.79
- 52 Week Low
- ACAD $13.40
- POR $39.55
- 52 Week High
- ACAD $25.23
- POR $49.85
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- POR 50.83
- Support Level
- ACAD $20.75
- POR $40.38
- Resistance Level
- ACAD $23.09
- POR $41.59
- Average True Range (ATR)
- ACAD 0.78
- POR 0.65
- MACD
- ACAD -0.20
- POR 0.14
- Stochastic Oscillator
- ACAD 9.83
- POR 76.96
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation.